9
Participants
Start Date
February 10, 2020
Primary Completion Date
October 17, 2024
Study Completion Date
December 17, 2025
Biospecimen Collection
Undergo blood sample collection
Cabozantinib S-malate
Given PO
Computed Tomography
Undergo CT
Ipilimumab
Given IV
Magnetic Resonance Imaging
Undergo MRI
Nivolumab
Given IV
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Commack, Commack
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Moffitt Cancer Center-International Plaza, Tampa
Moffitt Cancer Center - McKinley Campus, Tampa
Moffitt Cancer Center, Tampa
University of Kentucky/Markey Cancer Center, Lexington
Ohio State University Comprehensive Cancer Center, Columbus
Mayo Clinic in Rochester, Rochester
University of Kansas Cancer Center - Lee's Summit, Lee's Summit
University Health Truman Medical Center, Kansas City
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City
University of Kansas Cancer Center - North, Kansas City
Olathe Health Cancer Center, Olathe
University of Kansas Cancer Center, Kansas City
University of Kansas Clinical Research Center, Fairway
University of Kansas Hospital-Westwood Cancer Center, Westwood
University of Kansas Cancer Center-Overland Park, Overland Park
University of Kansas Health System Saint Francis Campus, Topeka
Ascension Via Christi - Pittsburg, Pittsburg
Salina Regional Health Center, Salina
HaysMed, Hays
University of Utah Sugarhouse Health Center, Salt Lake City
Huntsman Cancer Institute/University of Utah, Salt Lake City
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
USC Norris Oncology/Hematology-Newport Beach, Newport Beach
Memorial Sloan Kettering Basking Ridge, Basking Ridge
Memorial Sloan Kettering Monmouth, Middletown
Memorial Sloan Kettering Bergen, Montvale
National Cancer Institute (NCI)
NIH